Contribute Try STAT+ Today

A pill from Mirati Therapeutics developed to block the “undruggable” cancer protein called KRAS showed partial tumor responses in three patients with lung cancer and a single patient with colon cancer, according to preliminary results released Monday.

The first-in-human clinical data for the drug, called MRTX849, are scant — encompassing only 12 patients — but they are also significant, in that they will invigorate a debate that has simmered for months: Who has the superior KRAS-blocking drug: Mirati or Amgen?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy